Effect of prostaglandin analogues on anterior scleral thickness and corneal thickness in patients with primary open-angle glaucoma

Ji-Hye Park,Hyun Woo Chung,Yong Yeon Kim,Chungkwon Yoo

doi:10.1038/s41598-021-90696-4

Ji-Hye Park, Hyun Woo Chung + Show 2 more

Open Access

https://doi.org/10.1038/s41598-021-90696-4

Copy DOI

Journal: Scientific Reports	Publication Date: May 27, 2021
Citations: 14	License type: open-access

Affiliation: Korea University

Abstract

Prostaglandin (PG) analogues are usually prescribed as a first-line therapy in patients with glaucoma because of its once-daily dosing benefit and effective intraocular pressure (IOP) reduction. However, the mechanism of PG analogues is not completely understood. In this study, we investigated the effect of PG analogues on the anterior scleral thickness (AST) in treatment-naïve eyes with primary open-angle glaucoma using anterior segment optical coherence tomography. The AST was measured at the location of the scleral spur, 1000 μm, and 2000 μm posterior to the scleral spur and was compared before and after using the medications for 3 months and 1 year. Among 54 patients enrolled in this study, 31 patients used prostaglandin analogues and 23 patients used dorzolamide/timolol fixed combination (DTFC) drugs. There was no significant difference in untreated IOP, glaucoma severity, and baseline AST values between the two groups. While there was no significant changes in AST after using the DTFC drugs, the AST at all 3 locations showed a significant reduction in both the nasal and temporal sectors after using PG analogues for 1 year (all, P < 0.05). These findings suggest that the AST reduction after using PG analogues might be related with the increased uveoscleral outflow.

Highlights

Prostaglandin (PG) analogues are usually prescribed as a first-line therapy in patients with glaucoma because of its once-daily dosing benefit and effective intraocular pressure (IOP) reduction
There are several different classes of glaucoma medications that lower the intraocular pressure (IOP) by enhancing the aqueous outflow and/or by reducing the aqueous p roduction[4]; prostaglandin (PG) analogues, β-adrenergic receptor antagonists, adrenergic receptor agonists, carbonic anhydrase inhibitors, cholinergics and rho-kinase inhibitors. Among these topical glaucoma medications, prostaglandin analogues are usually prescribed as a first-line therapy in patients with glaucoma because of its once-daily dosing benefit and effective IOP reduction[5,6,7]
The patients in the PG group were younger than those in the dorzolamide/timolol fixed combination (DTFC) group, there was no significant difference in the untreated IOP, axial length, visual field (VF) parameters, retinal nerve fiber layer (RNFL) thickness, and anterior scleral thickness (AST) between the two groups

Summary

Introduction

Prostaglandin (PG) analogues are usually prescribed as a first-line therapy in patients with glaucoma because of its once-daily dosing benefit and effective intraocular pressure (IOP) reduction. OCT) and showed the usefulness of EDI OCT for visualizing the sclera clearly and measuring the anterior scleral thickness (AST)[22,23,24]. We evaluated the effect of topical prostaglandin analogues on the AST in treatment-naïve primary open-angle glaucoma (OAG) patients using EDI OCT.

Results

Conclusion